14-day Premium Trial Subscription Sign Up For FreeGet Free

Weaker Stock
Today AVXL ranks #16284 as sell candidate. Get a Free Stock at Robinhood
Stronger Stock

Anavex Life Sciences Corp. Stock Forecast NASDAQ:AVXL

$13.58 (2.72%)

Volume: 1M

Closed: Jan 19, 2022

Hollow Logo Score: -4.483

Anavex Life Sciences Corp. Stock Forecast

$13.58 (2.72%)

Volume: 1M

Closed: Jan 19, 2022

Score Hollow Logo -4.483

Anavex Life Sciences Corp. Company Profile

51 West 52nd Street

New York NY 10019



Industry: Biotechnology

Sector: Healthcare

Anavex Life Sciences Corp.


Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of Alzheimer’s disease, other central nervous system diseases, pain, and various cancers. The company’s lead drug candidates include ANAVEX 2-73 and ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil, which is in a Phase 2a clinical trial for the treatment of Alzheimer’s and other central nervous system diseases. Its preclinical drug candidates include ANAVEX 3-71, which uses ligands that activate sigma-1 receptors to treat Alzheimer’s disease; ANAVEX 1-41, a sigma-1 agonist that protects nerve cells from degeneration or death; and ANAVEX 1037 for the treatment of prostate cancer. The company was founded in 2006 and is based in New York, New York.

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE